Novo Nordisk (CPSE:NOVO B) Stock Still Looks Undervalued As Shares Fell 56%

What happened: Novo Nordisk shares trade at DKK 272.70 after a 55.9% decline over three years, and the article examines whether the current P/E reflects the earnings power of its GLP-1 portfolio. Key numbers: Share price DKK 272.70. Three-year decline 55.9%. P/E 10.6x versus Pharmaceuticals industry average 20.9x and peer group 35.7x. Why it matters: The Fair Ratio model points to a higher P/E than where the stock trades, so the market price screens as undervalued on that framework, while the bear case argues the price already reflects future launches and stable GLP-1 pricing.

Novo Nordisk shares trade at DKK 272.70 after a 55.9% decline over three years, and the article examines whether the current P/E reflects the earnings power of its GLP-1 portfolio.

The Fair Ratio model points to a higher P/E than where the stock trades, so the market price screens as undervalued on that framework, while the bear case argues the price already reflects future launches and stable GLP-1 pricing.